Maze Therapeutics (MAZE) Total Current Liabilities (2024 - 2026)

Maze Therapeutics has reported Total Current Liabilities for 3 years, with the latest figure at $21.2 million in Q1 2026.

• Quarterly Total Current Liabilities rose 14.07% year-over-year to $21.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $21.2 million (up 14.07% YoY) and the FY2025 annual result came in at $22.6 million, up 9.11% from the prior year.
• Total Current Liabilities eased to $21.2 million in Q1 2026 per MAZE's latest filing, from $22.6 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $22.6 million in Q4 2025 and troughed at $18.6 million in Q1 2025.
• A 3-year average of $20.8 million and a median of $21.0 million in 2024 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2025 and 2026: Total Current Liabilities rose 9.11% in 2025, then climbed 14.07% in 2026.
• Over 3 years, Total Current Liabilities stood at $20.7 million in 2024, then rose by 9.11% to $22.6 million in 2025, then declined by 5.85% to $21.2 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $21.2 million, $22.6 million, and $22.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.